Diurnal Glycemic Patterns during an 8-Week Open-Label Proof-of-Concept Trial of Empagliflozin in Type 1 Diabetes.

We recently reported improved glycemic control with reduced insulin dose in subjects with type 1 diabetes treated with the sodium glucose co-transporter-2 inhibitor empagliflozin. To further characterize the effects, we analyzed diurnal glycemic patterns by continuous glucose monitoring (CGM).In an...

Full beskrivning

Bibliografiska uppgifter

Huvudupphov:	Bruce A Perkins, David Z I Cherney, Nima Soleymanlou, Justin A Lee, Helen Partridge, Holly Tschirhart, Bernard Zinman, Roger Mazze, Nora Fagan, Stefan Kaspers, Hans-Juergen Woerle, Uli C Broedl, Odd Erik Johansen
Materialtyp:	Artigo
Språk:	Inglês
Utgiven:	Public Library of Science (PLoS) 2015-01-01
Serie:	PLoS ONE
Länkar:	http://europepmc.org/articles/PMC4636141?pdf=render
Taggar:	Lägg till en tagg Inga taggar, Lägg till första taggen!